Differentiating EPA from EPA/DHA in cardiovascular risk reduction.
Level 5 - mechanism / opinion, no new human data
Narrative review of clinical trials and mechanistic pharmacology without systematic review methodology.
PubMed 38559888 · doi:10.1016/j.ahjo.2022.100148
What was done
The authors reviewed clinical trial evidence (including REDUCE-IT and JELIS) and pharmacological mechanisms comparing purified eicosapentaenoic acid (EPA) monotherapy against combined EPA and docosahexaenoic acid (DHA) formulations for cardiovascular risk reduction.
What was found
Trials testing combined EPA and DHA failed to demonstrate cardiovascular outcome benefits despite lowering triglycerides. In contrast, 4 g daily of purified EPA in REDUCE-IT reduced atherosclerotic cardiovascular disease events by 25% compared with placebo (hazard ratio 0.75; 95% confidence interval 0.68-0.83; P < 0.001), with significant reductions in cardiovascular mortality, stroke, myocardial infarction, and revascularization. Differential effects were noted on membrane structure, lipoprotein oxidation, and inflammation resolution, alongside a proposed plasma EPA efficacy threshold of approximately 100 μg/mL.
Why it matters
This review highlights that cardiovascular risk reduction is specific to high-dose purified EPA rather than combination omega-3 formulations, likely driven by distinct cellular pharmacology and sufficient attained plasma levels.
Limits
This is a narrative review without a systematic search or meta-analytic pooling. No dedicated clinical trials of DHA monotherapy have been conducted, precluding direct comparison between pure EPA and pure DHA.
Cited by
- supports The REDUCE-IT trial tested a dose of 4 grams per day of omega-3 (EPA), which is five times higher than doses commonly used in previous omega-3 trials.